GPS Wealth Strategies Group LLC Has $2.25 Million Stake in Eli Lilly and Company (NYSE:LLY)

GPS Wealth Strategies Group LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,912 shares of the company’s stock after acquiring an additional 82 shares during the period. GPS Wealth Strategies Group LLC’s holdings in Eli Lilly and Company were worth $2,248,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Valley National Advisers Inc. grew its position in Eli Lilly and Company by 5.9% in the 4th quarter. Valley National Advisers Inc. now owns 4,573 shares of the company’s stock valued at $3,530,000 after purchasing an additional 255 shares during the period. McAdam LLC grew its holdings in shares of Eli Lilly and Company by 7.2% during the fourth quarter. McAdam LLC now owns 3,377 shares of the company’s stock valued at $2,607,000 after buying an additional 227 shares during the last quarter. River Street Advisors LLC increased its position in shares of Eli Lilly and Company by 0.6% during the fourth quarter. River Street Advisors LLC now owns 3,169 shares of the company’s stock worth $2,447,000 after acquiring an additional 20 shares in the last quarter. WFA Asset Management Corp acquired a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $108,000. Finally, U.S. Capital Wealth Advisors LLC lifted its position in Eli Lilly and Company by 134.1% in the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 20,176 shares of the company’s stock valued at $15,576,000 after acquiring an additional 11,556 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $811.47 on Tuesday. The firm’s 50 day moving average is $783.56 and its 200 day moving average is $843.75. The stock has a market capitalization of $770.35 billion, a P/E ratio of 87.73, a PEG ratio of 1.72 and a beta of 0.42. Eli Lilly and Company has a 12 month low of $682.53 and a 12 month high of $972.53. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company announced that its board has authorized a share buyback program on Monday, December 9th that permits the company to buyback $15.00 billion in outstanding shares. This buyback authorization permits the company to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s management believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be issued a $1.50 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.74%. The ex-dividend date is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Analyst Ratings Changes

Several analysts have recently commented on the company. Barclays lowered their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. Citigroup dropped their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Wells Fargo & Company reduced their target price on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Bank of America reiterated a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Finally, Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $997.50.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.